BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grywalska E, Sobstyl M, Putowski L, Roliński J. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. Int J Mol Sci 2019;20:E4705. [PMID: 31547532 DOI: 10.3390/ijms20194705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Lee WL, Wang PH. Aberrant sialylation in ovarian cancers. J Chin Med Assoc 2020;83:337-44. [PMID: 31904658 DOI: 10.1097/JCMA.0000000000000252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 20.0] [Reference Citation Analysis]
2 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Darmawi, Chen L, Su P, Liew P, Wang H, Weng Y, Huang R, Lai H. BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer. IJMS 2022;23:7158. [DOI: 10.3390/ijms23137158] [Reference Citation Analysis]
4 Sun D, Zhang A, Gao B, Zou L, Huang H, Zhao X, Xu D. Identification of Alternative Splicing-Related Genes CYB561 and FOLH1 in the Tumor-Immune Microenvironment for Endometrial Cancer Based on TCGA Data Analysis. Front Genet 2022;13:770569. [DOI: 10.3389/fgene.2022.770569] [Reference Citation Analysis]
5 Zhang C, Yang Q. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. Front Oncol 2020;10:572203. [PMID: 33634012 DOI: 10.3389/fonc.2020.572203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee WL, Wang PH. Immunology and ovarian cancers. J Chin Med Assoc 2020;83:425-32. [PMID: 32149893 DOI: 10.1097/JCMA.0000000000000283] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
7 Martínez-Campa C, Alonso-González C. Editorial for the Special Issue "New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies". Int J Mol Sci 2020;21:E4081. [PMID: 32521599 DOI: 10.3390/ijms21114081] [Reference Citation Analysis]
8 Aravantinou-Fatorou A, Andrikopoulou A, Liontos M, Fiste O, Georgakopoulou VE, Dimopoulos MA, Gavriatopoulou M, Zagouri F. Pembrolizumab in endometrial cancer: Where we stand now. Oncol Lett 2021;22:821. [PMID: 34691248 DOI: 10.3892/ol.2021.13082] [Reference Citation Analysis]
9 Russo L, Avesani G, Gui B, Trombadori CML, Salutari V, Perri MT, Di Paola V, Rodolfino E, Scambia G, Manfredi R. Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean J Radiol 2021;22:1310-22. [PMID: 34047505 DOI: 10.3348/kjr.2020.1299] [Reference Citation Analysis]
10 Kuznicki ML, Bennett C, Yao M, Joehlin-Price A, Rose PG, Mahdi H. Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population. Gynecol Oncol Rep 2020;34:100671. [PMID: 33294575 DOI: 10.1016/j.gore.2020.100671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ding H, Fan GL, Yi YX, Zhang W, Xiong XX, Mahgoub OK. Prognostic Implications of Immune-Related Genes' (IRGs) Signature Models in Cervical Cancer and Endometrial Cancer. Front Genet 2020;11:725. [PMID: 32793281 DOI: 10.3389/fgene.2020.00725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Drakes ML, Czerlanis CM, Stiff PJ. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers (Basel) 2020;12:E3301. [PMID: 33182298 DOI: 10.3390/cancers12113301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Holub K, Vargas A, Biete A. Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients. Clin Transl Oncol 2020;22:2040-8. [PMID: 32285291 DOI: 10.1007/s12094-020-02345-3] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Virarkar M, Vulasala SS, Morani AC, Waters R, Gopireddy DR, Kumar S, Bhosale P, Lall C. Neuroendocrine Neoplasms of the Gynecologic Tract. Cancers (Basel) 2022;14:1835. [PMID: 35406607 DOI: 10.3390/cancers14071835] [Reference Citation Analysis]
15 Li S, Dong C, Chen J, Gao X, Xie X, Zhang X. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma. Aging (Albany NY) 2021;13:16696-712. [PMID: 34158412 DOI: 10.18632/aging.203189] [Reference Citation Analysis]
16 Stern PL. Harnessing immunity for therapy in human papillomavirus driven cancers. Tumour Virus Res 2021;11:200212. [PMID: 33602657 DOI: 10.1016/j.tvr.2021.200212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Leskela S, Romero I, Rosa-Rosa JM, Caniego-Casas T, Cristobal E, Pérez-Mies B, Gutierrez-Pecharroman A, Santón A, Ojeda B, López-Reig R, Palacios-Berraquero ML, Andrada E, Montes S, Pastor F, Gomez MC, López-Guerrero JA, Poveda A, Palacios J. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification. Am J Surg Pathol 2020;44:982-90. [PMID: 32384322 DOI: 10.1097/PAS.0000000000001478] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
18 Caruso G, Sassu CM, Tomao F, Di Donato V, Perniola G, Fischetti M, Benedetti Panici P, Palaia I. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions. Crit Rev Oncol Hematol 2021;162:103344. [PMID: 33933568 DOI: 10.1016/j.critrevonc.2021.103344] [Reference Citation Analysis]
19 Dong Y, Lin L, Zeng C, He Z, Xu H. CD3D has the Potential to be a Prognostic Factor for Endometrial Carcinoma and an Indicator of Tumor Immune Microenvironment Regulation: a Study based on TCGA Data Mining. Indian J Gynecol Oncolog 2021;19. [DOI: 10.1007/s40944-021-00498-9] [Reference Citation Analysis]
20 Chen Q, Hu L, Huang D, Chen K, Qiu X, Qiu B. Six-lncRNA Immune Prognostic Signature for Cervical Cancer. Front Genet 2020;11:533628. [PMID: 33173530 DOI: 10.3389/fgene.2020.533628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
21 Bell SG, Uppal S, Sakala MD, Sciallis AP, Rolston A. An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab. Gynecol Oncol Rep 2021;37:100819. [PMID: 34258359 DOI: 10.1016/j.gore.2021.100819] [Reference Citation Analysis]
22 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Chen Y, Han L, Zheng A. Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis. Eur J Obstet Gynecol Reprod Biol 2021;268:74-81. [PMID: 34875557 DOI: 10.1016/j.ejogrb.2021.11.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]